Cochrane · systematic review · CD008018
Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure in premenopausal women
Chen, H, Xiao, L, Li, J, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 3 · 23.1%Very low 4 · 30.8%Low 4 · 30.8%Moderate 2 · 15.4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
GnRH agonist plus chemotherapy versus chemotherapy alone for the prevention of chemotherapy‐induced premature ovarian failure in premenopausal women
Population: premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Menstruation recovery or maintenance: GnRH agonist plus chemotherapy vs chemotherapy alone | RR 1.6 [1.14, 2.24] | 5 studies · 460 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Menstruation recovery or maintenance: GnRH agonist plus chemotherapy vs chemotherapy alone | RR 1.08 [0.95, 1.22] | 8 studies · 869 participants | Low Downgraded: risk of bias, inconsistency |
Premature ovarian failure GnRH agonist plus chemotherapy vs chemotherapy alone | RR 0.44 [0.31, 0.61] | 4 studies · 780 participants | Moderate Downgraded: risk of bias, imprecision |
Pregnancy GnRH agonist plus chemotherapy vs chemotherapy alone | RR 1.59 [0.93, 2.7] | 7 studies · 703 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Ovulation GnRH agonist plus chemotherapy vs chemotherapy alone | RR 2.47 [1.43, 4.26] | 2 studies · 95 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: hot flush GnRH agonist plus chemotherapy vs chemotherapy alone | RR 1.49 [0.16, 13.6] | 4 studies · 731 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse effects: vaginal dryness GnRH agonist plus chemotherapy vs chemotherapy alone | RR 1.18 [0.68, 2.04] | 2 studies · 488 participants | Moderate Downgraded: risk of bias, imprecision |
GnRH agonist‐antagonist cotreatment plus chemotherapy versus chemotherapy alone for the prevention of chemotherapy‐induced premature ovarian failure in premenopausal women
Population: premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Menstruation recovery or maintenance: GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone | RR 1 [0.76, 1.32] | 1 study · 50 participants | Very low Downgraded: risk of bias, imprecision |
Menstruation recovery or maintenance: GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone | RR 0.93 [0.56, 1.55] | 1 study · 50 participants | Very low Downgraded: risk of bias, imprecision |
Premature ovarian failure GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone | no estimate extracted | 0 participants | Ungraded |
Pregnancy GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone | RR 3 [0.13, 70.3] | 1 study · 50 participants | Very low Downgraded: risk of bias, imprecision |
Ovulation GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone | no estimate extracted | 0 participants | Ungraded |
Adverse events GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone | no estimate extracted | 0 participants | Ungraded |